Is CYCN or CYTK more undervalued in 2026?

CirclFi compares Cyclerion Therapeutics, Inc. (CYCN) and Cytokinetics, Incorporated (CYTK) using 13 institutional-grade valuation models. CYCN has a Quality of Company score of 5.5/10 while CYTK scores 5.9/10.

Which is a better buy — CYCN or CYTK?

Compare intrinsic values from 13 independent models against current market prices. CirclFi also calculates Value Trap scores. This is not financial advice — conduct your own analysis.

How do CYCN and CYTK valuations compare?

CYCN at $3.18 and CYTK at $76.81 are compared across Bayesian DCF, EPV, EROIC Spread, First Chicago, Markov DDM, and 8 additional models.

CYCN vs CYTK Valuation Comparison 2026 — Intrinsic Value Analysis

CYCN

Biotechnology

Cyclerion Therapeutics, Inc.

Quality

5.5

out of 10

Value Trap

SAFE

Price

$3.18

Last close

Models

9/13

Active

CYTK

Biotechnology

Cytokinetics, Incorporated

Quality

5.9

out of 10

Value Trap

LOW

Price

$76.81

Last close

Models

9/13

Active

Model-by-Model Comparison

Model	Type	CYCN Fair Value	CYCN Upside	CYTK Fair Value	CYTK Upside
Bayesian DCF	Intrinsic	$1.21	-62.0%	$24.22	-68.5%
Earnings Power Value	Intrinsic	—	—	$21.45	-67.2%
EROIC Spread	Intrinsic	$•••.••	••.•%	$•••.••	••.•%
First Chicago	Scenario	$•••.••	••.•%	$•••.••	••.•%
Markov DDM	Intrinsic	$•••.••	••.•%	$•••.••	••.•%
ML-RIV	Intrinsic	$•••.••	••.•%	$•••.••	••.•%
Dynamic NAV	Asset-Based	$8.67	+172.7%	—	—
PWERM	Option-Based	$•••.••	••.•%	$•••.••	••.•%
Regime Cross-Sectional	Relative	$•••.••	••.•%	$•••.••	••.•%
Sentiment SOTP	Hybrid	$•••.••	••.•%	$•••.••	••.•%
CUCE Ensemble	Ensemble	$•••.••	••.•%	$•••.••	••.•%
FTNN Topology	Relative	$•••.••	••.•%	$•••.••	••.•%

🔒

Unlock Full 13-Model Comparison

Access all valuation models for CYCN vs CYTK — including EROIC Spread, First Chicago, Markov DDM, PWERM, and 7 more.

Access Full Analysis — From $27/mo →

CYCN vs CYTK — Which Stock Is More Undervalued?

CYTK scores higher with a 5.9/10 quality rating vs CYCN's 5.5/10. Both stocks are analyzed daily using SEC EDGAR filings across 13 independent models.

Comparing Cyclerion Therapeutics, Inc. (CYCN) and Cytokinetics, Incorporated (CYTK) across 13 institutional-grade valuation models reveals how each company's intrinsic value stacks up against its market price. CirclFi's engine processes SEC EDGAR 10-K and 10-Q filings, FRED macroeconomic data, and GDELT news sentiment to generate independent fair value estimates daily.

CYCN currently trades at $3.18 with a QOC of 5.5/10, while CYTK trades at $76.81 with a QOC of 5.9/10.

Both companies are analyzed with models spanning intrinsic (Bayesian DCF, EPV), scenario-based (First Chicago), regime-switching (Markov DDM, RCMH-DCF), machine learning (ML-RIV, FTNN Topology), and ensemble methods (CUCE).